Pretransplantation pre-S2 and S protein heterogeneity predisposes to hepatitis B virus recurrence after liver transplantation

Liver Transplantation

Volumn 8, Issue 5, 2002, Pages 443-448

  Grottola, Antonella ^a   Buttafoco, Paola ^a   Del Buono, Maria Grazia ^a   Cremonini, Claudia ^a   Colantoni, Alessandra ^a   Gelmini, Roberta ^b   Morelli, Cristina ^c   Masetti, Michele ^b   Jovine, Elio ^b   Fruet, Fiorenza ^d   Pinna, Antonio ^b   Manenti, Federico ^a   Villa, Erica ^a  

^a Gastroenterology Unit   (Italy)

^b UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^c Department of Internal Medicine ^*  (Italy)

^d UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID; ANTIVIRUS AGENT; AZATHIOPRINE; CYCLOSPORIN A; EPITOPE; HEPATITIS B ANTIBODY; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B VACCINE; IMMUNOSUPPRESSIVE AGENT; INTERFERON; LAMIVUDINE; NUCLEOTIDE; STEROID; TACROLIMUS; VIRUS DNA; VITRONECTIN;

ADULT; AMINO ACID SUBSTITUTION; ARTICLE; B LYMPHOCYTE; CLINICAL ARTICLE; CONFORMATIONAL TRANSITION; CONTROLLED STUDY; DISEASE PREDISPOSITION; DNA DETERMINATION; DOSE RESPONSE; DRUG MECHANISM; DRUG TARGETING; FEMALE; GENE AMPLIFICATION; GENE SEQUENCE; GENETIC VARIABILITY; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LIVER TRANSPLANTATION; MALE; MISSENSE MUTATION; MUTATIONAL ANALYSIS; NONHUMAN; NUCLEOTIDE SEQUENCE; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; PROTEIN CONFORMATION; PROTEIN MODIFICATION; PROTEIN POLYMORPHISM; PROTEIN SECRETION; RECURRENCE RISK; RECURRENT INFECTION; RISK ASSESSMENT; TREATMENT FAILURE; VIRUS GENOME;

EID: 0036094860     PISSN: 15276465     EISSN: None     Source Type: Journal    
DOI: 10.1053/jlts.2002.32719     Document Type: Article

References (17)

1. Hepatitis B virus reinfection after orthotopic liver transplantation. Serological and clinical implications
2. Liver transplantation in European patients with hepatitis B surface antigen
3. Precore and contiguous regions of hepatitis B virus in liver transplantation for end-stage hepatitis B
4. Modulation of hepatitis B viral antigen expression by immunosuppressive drugs in primary hepatocyte culture
5. Hepatitis B virus with antigenically altered hepatitis B surface antigen is selected by high-dose hepatitis B immunoglobulin after liver transplantation
6. Incidence and clinical consequence of surface and polymerase gene mutations in liver transplant recipients on hepatitis B immunoglobulin
7. Hepatitis B virus S mutants in liver transplant recipients who were reinfected despite hepatitis B immune globulin prophylaxis
8. Hepatitis B virus mutations in the preS region before and after liver transplantation
9. Evidence for selection of hepatitis B mutants after liver transplantation through peripheral blood mononuclear cell infection
10. Properties of pre-S1 deletion mutants
11. Evidence for hepatitis B virus infection in patients with chronic hepatitis C with and without serological markers of hepatitis B
12. Nucleotide sequence of the hepatitis B virus genome (subtype ayw) cloned in E coli
13. Hepatitis B virus genotype A rarely circulates as an HBe-mutant: Possible contribution of a single nucleotide in the precore region
14. The small envelope protein is required for secretion of a naturally occurring hepatitis B virus mutant with pre-S1 deletion
15. Hepatitis B virus assembly is sensitive to changes in the cytosolic S loop of the envelope proteins
16. A dominant hepatitis B virus population defective in virus secretion because of several S-gene mutations from a patient with fulminant hepatitis
17. FK506 in liver transplantation for chronic hepatitis B: In vitro studies on lymphocyte activation and virus replication